Quiescence in R3327-G Rat prostate tumors after androgen ablation

Cancer Research

Volumn 57, Issue 12, 1997, Pages 2493-2500

  Pollack, Alan ^a   Lim Joon, Daryl ^a   Wu, Catherine S ^a   Sikes, Charles ^a   Hasegawa, Masatoshi ^a   Terry, Nicholas H A ^a   White, R Allen ^a   Zagars, Gunar K ^a   Meistrich, Marvin L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CLOXURIDINE;

ANIMAL TISSUE; ARTICLE; CANCER RISK; CATHETER ABLATION; CELL CYCLE S PHASE; CELL INTERACTION; CELL KILLING; CELL LOSS; FLOW CYTOMETRY; HIGH RISK POPULATION; IRRADIATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RAT;

ANIMALS; APOPTOSIS; CASTRATION; CELL COUNT; CELL DIVISION; FLOW CYTOMETRY; MALE; MITOTIC INDEX; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATS; S PHASE; TESTOSTERONE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 15144346419     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pollack, A., Zagars, G. K., and Kopplin, S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 32: 13-20, 1995.
2. Sands, M. E., Pollack, A., and Zagars, G. K. Influence of radiotherapy on nodepositive prostate cancer treated with androgen ablation. Int. J. Radiat. Oncol. Biol. Phys., 31: 13-19, 1995.
3. Pilepich, M. V., Krall, J. M., Al-Sarraf, M., John, M. J., Doggett, R. L. S., Saise, W. T., Lawton, C. A., Abrams, R. A., Rotman, M., Rubin, P., Shipley, W. U., Grignon, D., Caplan, R., and Cox, J. D. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology, 45: 616-623, 1995.
4. Humphries, J. E., and Isaacs, J. T. Unusual androgen sensitivity of the androgen-independent Dunning R-33327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Cancer Res., 42: 3148-3156, 1982.
5. Pollack, A., Irvin, G. L., Block, N. L., Lipton, R. M., Stover, B. J., and Claflin, A. J. Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors. Cancer Res., 42: 2184-2190, 1982.
6. Pollack, A., Block, N. L., Stover, B. J., Irvin, G. L., III. Fuentes, M. P., Claflin, A. J., and Malinin, T. I. In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy. J. Natl. Cancer Inst., 70: 907-914, 1983.
7. Parchuri, N., Wilson, G., and Meistrich, M. L. Protection of gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBF1 hybrid rats. J. Androl., 14: 257-266, 1993.
8. Meistrich, M. L., Wilson, G., Ye, W-S., Thrash, C., and Huhtaniemi, I. Relationship between hormonal treatments, suppression of spermatogenesis, and testicular protection from chemotherapy-induced damage. Endocrinology. 137: 3823-3831, 1996.
9. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
10. Abercrombie, M. Estimation of nuclear population from microtome sections. Anat. Rec., 94: 239-247, 1946.
11. White, R. A., Pollack, A., and Terry, N. H. A. Simultaneous cytokinetic measurement of aneuploid tumors and associated diploid cells following continuous labelling with chlorodeoxyuridine. Cytometry, 15: 311-319, 1994.
12. Pollack, A., Terry, N. H. A., Van, N. T., and Meistrich, M. L. Flow cytometric analysis of DNA, and the incorporation of two thymidine analogues in a mouse mammary tumor grown in vivo. Cytometry, 14: 168-172, 1993.
13. Pollack, A., White, R. A., Cao, S., Meistrich, M. L., and Terry, N. H. A. Calculating potential doubling time (Tpot) using monoclonal antibodies specific for two halogenated thymidine analogues. Int. J. Radiat. Oncol. Biol. Phys., 27: 1131-1139, 1993.
14. Terry, N. H. A., White, R. A., Meistrich, M. L., and Calkins, D. P. Evaluation of flow cytometric methods for determining population potential doubling times using cultured cells. Cytometry, 12: 234-241, 1991.
15. White, R. A., Fallon, J. F., and Savage, M. P. On the measurement of cytokinetics by continuous labeling with bromodeoxyuridine with applications to chick wing buds. Cytometry, 13: 553-556, 1992.
16. Berges, R. R., Vukanovic, J., Epstein, J. I., Carmichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implication of cell kinetic changes during progression of human prostatic cancer. Clin. Cancer Res., 1: 473-480, 1995.
17. Pollack, A., Block, N. L., Stover, B. J., and Irvin, G. L., III. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation. Cancer Res., 45: 1052-1057, 1985.
18. Westin, P., Stattin, P., Damber, J-E., and Bergh, A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 146: 1368-1375, 1995.
19. Westin, P., Bergh, A., and Damber, J-E. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate hut not in the highly differentiated Dunning R-3327PAP prostatic adenocarcinoma. Prostate, 22: 65-74, 1993.
20. Brändström, A., Westin, P., Bergh, A., Cajander, C., and Damber, J-E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res., 54: 3594-3601, 1993.
21. van Weerden, W. M., van Kreuningen, A., Elissen, N. M. J., de Vermeij, M., Jong, F. H., van Steenbrugge, G. J., and Schröder, F. H. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate, 23: 149-164, 1993.
22. Galle, M. P. W., van Steenbrugge, G-J., ten Kate, F. J. W., Schroeder, F. H., and van der Kwast, T. H. Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J. Natl. Cancer Inst., 79: 1333-1340, 1987.
23. English, H. F., Kloszewski, E. D., Valentine, E. G., and Samen, R. J. Proliferatiae response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res., 46: 839-844, 1986.
24. Oomens, E. H. G. M., van Steenbrugge, G. J., van der Kwast, Th. H., and Schröeder, F. H. Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferate cell fraction of human prostatic carcinoma. J. Urol., 145: 81-85, 1991.
25. 125I]iododeoxyuridine and triated thymidine methods. Cell Tissue Kinet., 10: 409-427, 1977.
26. Begg, A. C., McNally N. J., Shrieve, D., and Karcher, H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry, 6: 620-626, 1985.
27. 125I]Iododeoxyuridine as a prototype for radionuclide therapy with auger emitters. Nature (Lond.), 263: 620-621, 1977.
28. Zietman, A. L., Nakfoor, B. M., Prince, E. A., Gerweck, L. E., and Shipley, W. U. The effect of androgen deprivation on an androgen-sensitive tumor: an in vitro and in vitro study. Cancer J. Sci. Am., 3: 31-36, 1997.
29. Berchem, G. J., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
30. Lim Joon, D., Hasegawa, M., Wu, C. S., Sikes, C., Khoo, V. S., Zagars, G. K., Terry, N. H. A., Meistrich, M. L., and Pollack, A. Supra-additive apoptotic response in predominantly quiescent prostate tumors when treated with androgen ablation and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 36 (Suppl. 1): 191, 1996.